In this proposal, we plan to measure Apo A-I post-translational modifications (PTMs) in 150 samples from subjects with and without type 2 diabetes, together with HDL cholesterol efflux function and the ability of Apo A-I to activate lecithin cholesterol acyltransferase (LCAT) enzyme.

NIH Funding Acknowledgment: Important - All publications resulting from the utilization of SC CTSI resources are required to credit the SC CTSI grant by including the NIH funding acknowledgment and must comply with the NIH Public Access Policy.